Icure Pharmaceutical Incorporation Balance Sheet Health
Financial Health criteria checks 1/6
Icure Pharmaceutical Incorporation has a total shareholder equity of ₩59.6B and total debt of ₩76.3B, which brings its debt-to-equity ratio to 128%. Its total assets and total liabilities are ₩166.1B and ₩106.5B respectively.
Key information
128.0%
Debt to equity ratio
₩76.30b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩8.56b |
| Equity | ₩59.59b |
| Total liabilities | ₩106.54b |
| Total assets | ₩166.14b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A175250's short term assets (₩31.1B) do not cover its short term liabilities (₩95.4B).
Long Term Liabilities: A175250's short term assets (₩31.1B) exceed its long term liabilities (₩11.1B).
Debt to Equity History and Analysis
Debt Level: A175250's net debt to equity ratio (113.7%) is considered high.
Reducing Debt: A175250's debt to equity ratio has increased from 24.8% to 128% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A175250 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: A175250 has less than a year of cash runway if free cash flow continues to grow at historical rates of 7.4% each year.